Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… EVOXAC (cevimeline HCl) Capsules, 30 mg, SnowBrand NDA 20-989 1/11/00 1/19/00 1/19/00 3/12/02 EVOXAC Indication: for the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. | EVOXAC (cevimeline HCl) Capsules, Daiichi Pharma, Labeling Revision | EVOXAC (cevimeline HCl) Capsules, Daiichi-Sankyo Pharma, Labeling Revision | Cevimeline Hydrochloride Capsules, Roxane Laboratories, Inc., Tentative Approval | Cevimeline Hydrochloride Capsules, Apotex Corp., Approval ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com